NCT05660447View on ClinicalTrials.gov

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

January 31, 2025

Conditions
Rhegmatogenous Retinal DetachmentProliferative Vitreoretinopathy
Interventions
DRUG

Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]

One drop of rho-kinase (ROCK) inhibitor in the vitrectomized eye, once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56

DRUG

Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud

Patients enrolled in the control group will receive a placebo (one drop of artificial tears) once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56

Trial Locations (1)

19107

Wills Eye Physicians - Mid Atlantic Retina, Philadelphia

All Listed Sponsors
lead

Wills Eye

OTHER